allogeneic anti-CD19 CAR T cells ATA3219
A preparation of allogeneic human Epstein-Barr virus (EBV)-sensitized T lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), with a modified CD3zeta signaling domain 1xx, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD19 CAR T cells ATA3219 recognize and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The use of allogeneic EBV T cells minimizes the risks for graft-versus-host disease (GvHD). The modified CD3zeta signaling domain 1xx retains signaling capacity in 1 of 3 immune-receptor-tyrosine-based-activation-motif (ITAM) regions, which may help prevent counterproductive T-cell differentiation and exhaustion, and may enhance the anti-tumor activity of the CAR T-cells.
Synonym: | allogeneic anti-CD19 CAR-T cells ATA3219 |
---|---|
Code name: | ATA 3219 ATA-3219 ATA3219 |